This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sastre-Garriga, J Articles by Montalban, X Search for Related Content PubMed PubMed Citation Articles by Sastre-Garriga, J Articles by Montalban, X Social Bookmarking                         What's this?

APS and the brain

Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d’Hebron, Barcelona, Spain

X Montalban

Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d’Hebron, Barcelona, Spain, xmontal{at}hg.vhebron.es

Antiphospholipid antibody syndrome (APS) may present with neurological syndromes. Cerebrovascular disease, chorea/ballismus, epileptic seizures, headache, cognitive impairment, transverse myelopathy, Devic’s syndrome and multiple sclerosis-like presentations feature among others. Cerebrovasculardisease is one of the most common presentingsymptoms of APS, second only to deep vein thrombosis, and accounts for half of neurological manifestations in patients with APS; accelerated atherogenesis and cardioembolism are the most likely mechanisms implicated. Though infrequent, chorea is consistently associated with APS; the pathogenetic role of antiphospholipid antibodies (APLab) in this case might be routed through cerebrovasculardisease in some cases and through purely immunological pathways in others. Both ischemic and immunological mechanisms have been demonstrated in the pathogenesis of epileptic seizures, which may account for 7% of neurological manifestations in APS. Although frequent in APS, a causative link between APLab and most common types of headache (migraine and tension-type headache) is more than dubious. Cognitive impairment may derive from a well-defined clinical tableau of multi-infarct dementia. Nevertheless, (highly frequent) less severe cognitive impairment has also been associated with the presence of APLab in the absence of magnetic resonance findings. A relationship between APS and transverse myelopathy seems likely but small numbers in the studies published to date preclude definite statements; routinely testing for APLab patients with neurological manifestations suggestive of multiple sclerosis seems to be unrecommended at the present time.

Key Words: anticardiolipin antibodies • antiphospholipid syndrome • chorea • migraine • multiple sclerosis • stroke • systemic lupus erythematosus • transverse myelitis

Lupus, Vol. 12, No. 12, 877-882 (2003)
DOI: 10.1191/0961203303lu496oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. M. Wani, W. M. Hussain, M. I. Fatani, A. Qadmani, G. A. A. Maimani, A. Turkistani, K. S Dairi, A. Abumatar, and M. G Bafaraj Lower cranial nerve palsy, aseptic meningitis and hydrocephalus: unusual presentation of primary antiphospholipid syndrome BMJ Case Reports, August 27, 2009; 2009(aug27_1): bcr0620092013 - bcr0620092013. [Abstract] [Full Text]

				C. Kowal, L. A. DeGiorgio, J. Y. Lee, M. A. Edgar, P. T. Huerta, B. T. Volpe, and B. Diamond From the Cover: Human lupus autoantibodies against NMDA receptors mediate cognitive impairment PNAS, December 26, 2006; 103(52): 19854 - 19859. [Abstract] [Full Text] [PDF]

				P. T. Huerta, C. Kowal, L. A. DeGiorgio, B. T. Volpe, and B. Diamond Immunity and behavior: Antibodies alter emotion PNAS, January 17, 2006; 103(3): 678 - 683. [Abstract] [Full Text] [PDF]

				L Barile-Fabris, R Ariza-Andraca, L Olguin-Ortega, L J Jara, A Fraga-Mouret, J M Miranda-Limon, J Fuentes de la Mata, P Clark, F Vargas, and J Alocer-Varela Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus Ann Rheum Dis, April 1, 2005; 64(4): 620 - 625. [Abstract] [Full Text] [PDF]

				S. Ferreira, D. P. D'Cruz, and G. R. V. Hughes Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand? Rheumatology, April 1, 2005; 44(4): 434 - 442. [Abstract] [Full Text] [PDF]

				J. A. Gomez-Puerta, R. Cervera, L. M. Calvo, B. Gomez-Anson, G. Espinosa, G. Claver, S. Bucciarelli, A. Bove, M. Ramos-Casals, M. Ingelmo, et al. Dementia associated with the antiphospholipid syndrome: clinical and radiological characteristics of 30 patients Rheumatology, January 1, 2005; 44(1): 95 - 99. [Abstract] [Full Text] [PDF]